Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

They could perhaps see sustained runs beyond this year.

So far this month, investors have poured $2.6 billion into follow-on rounds for public biotechs — the most ever for the pre-JPM timespan.

A life sciences hub in Syracuse is getting a major upgrade as New York pushes to grow its biotechnology sector. Gov. Kathy Hochul announced Monday that the state will invest nearly $3 million to ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Hands-on biotech training delivers credentials, research projects, and real lab access for San Antonio students—fueling ...

Now, it’s worth noting Stock Advisor’s total average return is 949 % — a market-crushing outperformance compared to 195% for ...

Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

Developed through Debut’s proprietary platform integrating AI, skin genomics and biotechnology, DermCeutical EDL biologically ...